Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2‐Positive Early Stage Breast Cancer: A Single Center Experience

OBJECTIVES. Trastuzumab (H) and pertuzumab (P) with standard chemotherapy is approved for use in the neoadjuvant setting for human epidermal growth receptor 2 ‐positive patients. A retrospective analysis was performed of patients treated with dose‐dense (dd) doxorubicin and cyclophosphamide (AC) fol...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncologist
Main Authors: Singh, Jasmeet C., Mamtani, Anita, Barrio, Andrea, Morrow, Monica, Sugarman, Steven, Jones, Lee W., Yu, Anthony F., Argolo, Daniel, Smyth, Lilian M., Modi, Shanu, Schweber, Sarah, Boafo, Camilla, Patil, Sujata, Norton, Larry, Baselga, Jose, Hudis, Clifford A., Dang, Chau
Format: Artigo
Sprog:Inglês
Udgivet: AlphaMed Press 2017
Fag:
Breast Cancer
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5330708/
https://ncbi.nlm.nih.gov/pubmed/28167568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0268
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker